Vor Biopharma (NASDAQ:VOR) Issues Earnings Results

Vor Biopharma (NASDAQ:VOR) released its quarterly earnings results on Tuesday. The company reported ($0.80) EPS for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.11), Zacks reports.

Vor Biopharma Stock Up 0.9%

Shares of VOR opened at $23.59 on Wednesday. The stock has a 50-day moving average of $18.00 and a two-hundred day moving average of $15.88. Vor Biopharma has a one year low of $6.50 and a one year high of $50.20.

Analyst Ratings Changes

A number of brokerages have recently weighed in on VOR. Jefferies Financial Group upgraded Vor Biopharma to a “strong-buy” rating in a research note on Thursday, April 30th. HC Wainwright reaffirmed a “buy” rating and issued a $31.00 price objective on shares of Vor Biopharma in a research report on Monday, May 18th. Wedbush lifted their target price on shares of Vor Biopharma from $15.00 to $18.00 and gave the stock a “neutral” rating in a research note on Thursday, May 14th. Weiss Ratings raised shares of Vor Biopharma from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, June 30th. Finally, Wall Street Zen lowered shares of Vor Biopharma from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Two analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $42.25.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the company. Goldman Sachs Group Inc. lifted its holdings in shares of Vor Biopharma by 218.2% during the first quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company’s stock worth $61,000 after purchasing an additional 58,247 shares during the period. XTX Topco Ltd purchased a new position in Vor Biopharma during the 2nd quarter worth approximately $66,000. Susquehanna Portfolio Strategies LLC purchased a new position in Vor Biopharma during the 4th quarter worth approximately $134,000. Jane Street Group LLC acquired a new stake in Vor Biopharma during the 1st quarter valued at approximately $140,000. Finally, Persistent Asset Partners Ltd acquired a new stake in Vor Biopharma during the 4th quarter valued at approximately $141,000. 97.29% of the stock is currently owned by hedge funds and other institutional investors.

About Vor Biopharma

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).